If you have been reading about Regulatory peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-13. Numbers and descriptions here follow the published literature rather than marketing material.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.
Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.
| Property | Value | Notes |
|---|---|---|
| Common route | Intranasal | Also injected in some animal work |
| Solubility class | Freely soluble in water | Solid form is hygroscopic |
| Typical storage | About -20 degrees Celsius | Keep desiccated and dark |
| Purity method | Reverse-phase HPLC | Reported as area percent |
| Confirmatory method | Mass spectrometry | Verifies expected molecular mass |
Once dissolved, the peptide is markedly less stable than the dry powder. Aqueous solutions are subject to backbone hydrolysis and to microbial growth when they are handled without sterile technique. Buffered solutions near neutral pH are common for short-term laboratory work, while acidic conditions are sometimes used to improve solubility. Analytical laboratories generally prepare working solutions fresh rather than storing them, and a residual water film left in a reopened vial can seed degradation even when the container appears dry.
Reversed-phase high-performance liquid chromatography is the standard technique for estimating peptide purity. The result is a peak-area percentage, which describes how much of the detected material elutes as the main peak in one run. Mass spectrometry confirms the molecular mass and can reveal truncated, adducted, or otherwise modified species. Amino acid analysis or tandem mass spectrometry can address sequence fidelity when identity is in doubt. None of these measurements, taken alone, establishes that a sample is fit for any specific purpose.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
=== Early life and education === Matt Little was born and raised in Lakeville, Minnesota, graduating from Rosemount High School in 2003 before earning a bachelor's degree in political science from the University of Minnesota Morris in 2007. Little worked as a regional field coordinator for the National Association of Letter Carriers in Washington, D.C., for two years and spent a year teaching English in Chile before attending the University of Minnesota Law School. In 2014, he earned his Juris Doctor, graduating magna cum laude.
248Cm(13C,xn)261−xNo (x=3?,4,5) This reaction was first studied in 1967 at the LBNL. The new isotopes 258No,257No and 256No were detected in the 3-5n channels. The reaction was repeated in 1970 to provide further decay data for 257No.
== See also == Substituted tryptamine List of investigational hallucinogens and entactogens List of investigational anxiolytics List of investigational antidepressants SPL028 (D2-DMT; α,α-dideutero-DMT) Deuterated 5-MeO-DMT α,α-Dideuterotryptamine
Sources: en.wikipedia.org
Posterior pituitary In the hypothalamic–pituitary–adrenal axis, neurohypophysial hormones are released from the posterior pituitary, which is actually a prolongation of the hypothalamus, into the circulation.
French Guiana - Scouting in French Guiana Guadeloupe and Saint Martin - Scouting in Guadeloupe et Saint Martin Martinique - Scouts et Guides de Martinique Mayotte - Scouting in Mayotte New Caledonia - Scouting in New Caledonia Réunion - Scouting on Réunion Saint Pierre and Miquelon - Scouting in Saint Pierre and Miquelon Wallis and Futuna - Scouting in Wallis and Futuna New Zealand
=== Implantable devices === The development of implantable devices like pacemakers and spinal cord stimulators also began in the mid-20th century. Devices to manage pain received FDA (USA) approval in the late 1960s. In 1967, Dr. Norm Shealy from Western Reserve Medical School presented "the first dorsal column stimulator for pain control". It was developed based on the Gate Theory of Wall and Melzack, which stated that pain transmissions from tiny nerve fibers would be blocked if competing transmissions were made along larger sensory nerve fibers. In 1973, Prof Hosbuchi reported relieving the denervation facial pain of anesthesia dolorosa via lasting electrical stimulation of the somatosensory thalamus, which marked the beginning of the age of deep-brain stimulation. In 1987, the team of neurosurgeons/neurologists Professor Benabid and Professor Pollak and their colleagues (Grenoble, France) published results on this topic about thalamic Deep Brain Stimulation. Deep brain stimulation began to be used to treat motor symptoms of movement disorders such as Parkinson's disease. In 1989, the International Neuromodulation Society (INS) was founded in Paris after the first International Congress on Epidural Spinal Cord Stimulation in Groningen, the Netherlands, by a select group of physicians: Dr. Augustinsson, a Swedish neurosurgeon; Dr. Galley, a French cardiologist; Dr. Illis, a British neurologist; Dr. Kranick, a German neurosurgeon: Dr. Meglio, an Italian Neurosurgeon; Dr. Sier, a Dutch vascular surgeon and Dr. Staal, a Dutch neurosurgeon.
Within a generation, the Norman elite abandoned Old Norse for the Gallo-Romance language that would evolve into Norman French. They also converted to Christianity, but did so while retaining a distinct warrior ethos. This fusion is evident in the popularity of given names; while Old Norse names like Hrólfr (Rollo) and Ansteinn (Osten) were initially common, they were quickly Latinized or replaced by Christian names, yet the martial spirit remained central to their identity. In many ways they would seem "more French than the French". The descendants of Vikings replaced the Norse religion and Old Norse language with Catholicism (Christianity) and the Langue d'oil of the local people, descending from the Latin of the Romans. The Norman language (Norman French) was forged by the adoption of the indigenous langue d'oïl branch of Romance by a Norse-speaking ruling class, and it developed into the French regional languages that survive today. The new Norman rulers were culturally and ethnically distinct from the old French aristocracy, most of whom traced their lineage to the Franks of the Carolingian dynasty from the days of Charlemagne in the 9th century. By intermarrying with the local aristocracy and adopting the growing feudal doctrines of the rest of France, the Normans would progressively work these principles into a functional hierarchical system in their own duchy, and later export it to Norman dominated England. The Norman population outside the Viking settler elite were overwhelmingly locals of West Francia.
Sources: en.wikipedia.org
== Delivery == Granzyme B is released with perforin which inserts into a target cell's plasma membrane forming a pore. Perforin has a radius of 5.5 nm and granzyme B has a stokes radius of 2.5 nm and can therefore pass through the perforin pore into the target to be destroyed. Alternatively, once released, granzyme B can bind to negatively charged heparan sulfate containing receptors on a target cell and become endocytosed. The vesicles that carry the enzyme inside then burst, exposing granzyme b to the cytoplasm and its substrates. Hsp-70 has also been linked to aiding granzyme B entry. Granzyme B has also been proposed to enter a target by first exchanging its bound serglycin for negative phospholipids in a target's plasma membrane. Entry then occurs by the less selective process of absorptive pinocytosis.
==== Second state of emergency: June 1986 ==== The partial emergency was lifted on 7 March 1986, only to be replaced on 12 June – in the run-up to the tenth anniversary of the Soweto uprising on 16 June – by a second, far more stringent state of emergency, now applying across the country. Among other things, the new order empowered any member of the police or army to use any kind of force deemed necessary to clear an area. With the death toll by then "far in excess of 1,600", Botha told Parliament, "I am of the opinion that the ordinary laws of the land at present on the statute book are inadequate to enable the government to insure the security of the public and to maintain public order". The government said that it detained more than 1,000 people on the first day of the emergency; 30,000 were detained by August 1987. Indeed, the primary use of the emergency orders was to enable mass and indefinite detention of those viewed by the government as the ringleaders or instigators of the unrest. Critics of the government argued that this was deeply counterproductive, as the putative ringleaders were generally "simply the most articulate and experienced activists", the removal of whom "created a political vacuum into which unruly, undisciplined elements surged". In the phrase of the UDF's Murphy Morobe (speaking to press while in hiding to evade arrest), "Removing responsible leaders of the people has effectively paved the way for a blood bath". Desmond Tutu lamented as early as May 1986 that the government "have arrested the very people they should be talking to...
== Gametology == Gametology denotes the relationship between homologous genes on non-recombining, opposite sex chromosomes. The term was coined by García-Moreno and Mindell. 2000. Gametologs result from the origination of genetic sex determination and barriers to recombination between sex chromosomes. Examples of gametologs include CHDW and CHDZ in birds.
== Exceptions == Genetics does not determine the language spoken by a human being, and the link between Y-chromosomal haplogroups and linguistic affinities is an observed correlation and not a causal link. While father tongues predominate, exceptions to father tongues exist in the world. One possible exception is the Balti in northern Pakistan. The mtDNA haplogroups most frequent among Balti are the same as those of the neighbouring Tibetan communities, whereas the Y-chromosomal haplogroups most frequent in Balti males appear to have entered Baltistan from the west with the introduction of Islam. The Balti speak one of the most conservative Tibetan languages. The language of the Balti corresponds to the mtDNA and not to the Y chromosome and is in effect a salient example of a mother tongue.
holocentric (of a linear chromosome or chromosome fragment) Having no single centromere but rather multiple kinetochore assembly sites dispersed along the entire length of the chromosome. During cell division, the chromatids of holocentric chromosomes move apart in parallel and do not form the classical V-shaped structures typical of monocentric chromosomes.
Sources: en.wikipedia.org
Most published work uses intranasal application, either as drops or as a nasal spray. Injection routes appear in a smaller set of animal experiments. Oral use is uncommon in the literature because peptide breakdown and poor absorption limit this route.
Reported human trials are few, brief and originate mainly from one country. They describe effects on anxiety-related measures, but sample sizes are small and reporting is limited. The results are widely regarded as preliminary rather than confirmed.
Reverse-phase liquid chromatography is used to assess purity and separation of related impurities. Mass spectrometry confirms that the observed molecular mass matches the expected peptide. A certificate of analysis from the supplier is the usual document of record.
Purity is usually reported as an HPLC area percentage, most often measured at 214 nm. Identity is confirmed separately by mass spectrometry. A certificate of analysis should state both the method and the observed value.